Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases
Abstract
Background Chronic diseases are a major cause of mortality worldwide, and despite the recent development in treatment modalities, synthetic drugs have continued to show toxic side effects and development of chemoresistance, thereby limiting their application. The use of phytochemicals has gained attention as they show minimal side effects. Diosgenin is one such phytochemical which has gained importance for its efficacy against the life-threatening diseases, such as cardiovascular diseases, cancer, nervous system disorders, asthma, arthritis, diabetes, and many more.Aim To evaluate the literature available on the potential of diosgenin and its analogs in modulating different molecular targets leading to the prevention and treatment of chronic diseases.Method A detailed literature search has been carried out on PubMed for gathering information related to the sources, biosynthesis, physicochemical properties, biological activities, pharmacokinetics, bioavailability and toxicity of diosgenin and its analogs.Key findings The literature search resulted in many in vitro, in vivo and clinical trials that reported the efficacy of diosgenin and its analogs in modulating important molecular targets and signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, NF-κB, MAPK, etc., which play a crucial role in the development of most of the diseases. Reports have also revealed the safety of the compound and the adaptation of nanotechnological approaches for enhancing its bioavailability and pharmacokinetic properties.Significance Thus, the review summarizes the efficacy of diosgenin and its analogs for developing as a potent drug against several chronic diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Diosgenin reportedly interacts with several signaling pathways, including NF-κB, JAK/STAT, PI3K/AKT/mTOR, and MAPK.
“Like 20E, DSG reportedly interacts with several signaling pathways, including NF-κB, JAK/STAT, and PI3K/AKT/mTOR as well as MAPK and several others [45].”
From How reliable is the labeling of a commercial phytosteroid product? A 12-week randomized double-blind training study (2025) · cites this paper as [45]
The citation lists haven’t been fetched yet
References 404 · Cited by 155
- Authors
- Parama, D., Boruah, M., Yachna, K., Rana, V., Banik, K., Harsha, C., Thakur, K. K., Dutta, U., Arya, A., Mao, X., Ahn, K. S., & Kunnumakkara, A. B.
- Affiliations
- Indian Institute of Technology Guwahati (IN)
- Cotton University (IN)
- Taylor's University (MY)
- Guangzhou University of Chinese Medicine (CN)
- Kyung Hee University (KR)
- Corresponding author
- Ahn, Kwang Seok
- Kunnumakkara, Ajaikumar B.
- ORCID
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 260
- Pages
- 118182
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3047776760
- Cited by
- 155
- References
- 404
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 30 · 2023: 19 · 2022: 33 · 2021: 30 · 2020: 4
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Life Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phytochemical Studies and Bioactivities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Natural product bioactivities and synthesis
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Medicinal Plant Research
- Keywords
- diosgenin, steroidal saponins, chronic disease, phytochemicals, cardiovascular disease, cancer, neurodegenerative diseases, diabetes mellitus, arthritis, asthma, signaling pathways, PI3K/AKT/mTOR pathway, NF-κB, mitogen-activated protein kinase, JAK/STAT signaling, bioavailability, pharmacokinetics, nanotechnology, drug toxicity
- MeSH terms
- Animals, Biological Availability, Cardiovascular Diseases, Chronic Disease, Diosgenin, Humans, Inflammation, Phytotherapy, Neoplasms, Nervous System Diseases, Seeds, Signal Transduction, Trigonella, PubMed, Chemical Phenomena
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review